Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises specific heavy chain variable region (VH) and light chain variable region (VL) sequences as claimed, T cells expressing such a CAR are useful in the treatment of some cancers